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The cysteine protease calpain-I is linked to several diseases and is therefore a valuable target for inhibition.
Selective inhibition of calpain-I has proved diﬃcult as most compounds target the active site and inhibit a
broad spectrum of cysteine proteases as well as other calpain isoforms. Selective inhibitors might not only
be potential drugs but should act as tools to explore the physiological and pathophysiological roles of
calpain-I. a-Mercaptoacrylic acid based calpain inhibitors are potent, cell permeable and selective
inhibitors of calpain-I and calpain-II. These inhibitors target the calcium binding domain PEF(S) of
calpain-I and -II. Here X-ray diﬀraction analysis of co-crystals of PEF(S) revealed that the disulﬁde form
of an a-mercaptoacrylic acid bound within a hydrophobic groove that is also targeted by a calpastatin
inhibitory region and made a greater number of favourable interactions with the protein than the
reduced sulfhydryl form. Measurement of the inhibitory potency of the a-mercaptoacrylic acids and X-
ray crystallography revealed that the IC50 values decreased signiﬁcantly on oxidation as a consequence
of the stereo-electronic properties of disulﬁde bonds that restrict rotation around the S–S bond.
Consequently, thioether analogues inhibited calpain-I with potencies similar to those of the free
sulfhydryl forms of a-mercaptoacrylic acids.Introduction
Calpain-I and calpain-II are the two most studied members of a
family of calcium dependent cysteine proteases that currently
comprises een identied gene products in humans.1–3 These
heterodimeric proteases are composed of a large subunit with a
molecular mass of 80 000 and a small subunit of mass
30 000. Calpain-I and calpain-II share a small subunit, which
consists of two domains, a penta-EF hand calcium binding
domain PEF(S) and a glycine rich domain that is thought to
interact with cellular membranes;4 the large subunits of cal-
pain-I and -II possess 62% sequence similarity in humans5 and
comprise four distinct domains, a N-terminal anchor helix, the
active site domain (CysPc), a domain that resembles the C2
membrane binding domains of phosphokinases and is hence
known as the C2L domain,2,6 and a second penta-EF hand
calcium binding domain known as PEF(L). PEF(L) is the domain
that determines the concentration of calcium required for
protease activation, which is the discriminating factor between
the two isoforms.1,7 Calpain-I is activated in vitro byin Building, Park Place, Cardiﬀ, UK, CF10
: +44 (0) 29 208 74030; Tel: +44 (0) 29
of Medicine, Heath Campus, Cardiﬀ, UK,
tion (ESI) available. See DOI:
hemistry 2015approximately 50 mM Ca2+, whereas calpain-II requires approx-
imately 350 mM Ca2+ for activation.1
Numerous physiological processes have been linked with
calpain-I and -II, including cell motility,8–10 apoptosis11,12 and
progression through the cell cycle13 but the precise roles of
these proteases remain poorly understood, which is at least in
part due to a lack of specic inhibitors that allow selective
knockout or knock-down of their cellular activities.14 Other
techniques such as microinjection of a surplus of the enzymes
or the release of calcium ions into cells have been used to
activate the enzymes to explore their cryptic roles in vivo. The
majority of synthetic inhibitors available to examine the role of
these isoforms are generic cysteine protease inhibitors that
react with the active site cysteine and hence show little
discrimination between calpain isoforms or indeed other
cysteine proteases such as caspases or cathepsins.15–17 The cal-
pain system includes an endogenous inhibitor, calpastatin
(CAST), a large protein that only binds to members of the cal-
pain family that form a heterodimeric complex, hence
discriminating between calpains and other cysteine proteases.
Specic cell permeable inhibitors of calpain(s) that target the
CAST binding sites could be used as valuable cell-biological
tools for the elucidation of the cryptic physiological and path-
ophysiological roles of calpain isoforms and potentially as
drugs to treat conditions such as autoimmune diseases,
ischemic stroke damage and cancer.14,18,19
A previous investigation led to the discovery of novel, iso-
form-selective inhibitors that target calpain through interac-
tions with allosteric binding sites.17 The a-mercaptoacrylic acidsChem. Sci., 2015, 6, 6865–6871 | 6865
Fig. 1 Structures of PD150606 (1), PD151746 (2), (Z)-3-(6-bro-
moindol-2-yl)-2-mercaptoacrylic acid (3) and (2Z,20Z)-2,20-disul-
fanediylbis(3-(6-bromoindol-3-yl)acrylic acid) (4).20,24




















































































View Article OnlinePD150606 (1) and PD151746 (2) (Fig. 1)20 bind to the calcium
binding domain of calpain rather than the active site and show
modest selectivity for calpain-I over calpain-II.21,22 The hydro-
phobic pocket of PEF(S) targeted by these inhibitor is also
bound by the inhibitory region C of calpastatin domain IV,
where Leu 660 is embedded in the pocket.23 Based on
compounds 1 and 2, potent cell permeable inhibitors of cal-
pain-I that inhibit the cell spreading action of live neutrophils in
vitro were synthesised.24,25 A single co-crystal X-ray structure
showed that like PD150606 the new compounds bound to the
calcium binding domain PEF(S).24,26 The thiol and carboxylic
acid groups of the inhibitors are critical for activity20,27 but
somewhat surprisingly these functional groups point away from
the protein into solution. Here we report that oxidation of the
sulydryls of these a-mercaptoacrylic acids to form disuldes
leads to inhibitors with greatly enhanced potency, where one
half of the compound targets the hydrophobic CAST binding
groove of PEF(S). This previously unexplored mode of action
opens the way for the development of a new generation of stable
and selective inhibitors of calpain-I.Results and discussion
The interaction of (Z)-3-(6-bromoindole-3-yl)-2-mercaptoacrylic
acid (3) (Fig. 1) with human PEF(S) was investigated by single
crystal X-ray crystallography. Human PEF(S) was produced in E.
coli, puried to apparent homogeneity, crystallised and soaked
with 3 as previously described for other a-mercaptoacrylic
acids.26,28 Similar to other PEF(S) a-mercaptoacrylic acid co-
crystal structures, 3 bound to the hydrophobic pocket of PEF(S)
in the region that also binds Leu 660 of the CAST domain IV
inhibitory region C. This is situated between the second and
fourth a-helices (Fig. 2).21–23,26 The hydrophobic and carbonyl
portions of 3match the spatial orientation of Leu 660, but many
unexplored possibilities appear to exist for hydrophobic
contacts corresponding to preceding residues in the a-helix of
CAST inhibitory region C (Fig. 2).23 The hydrophobic pockets6866 | Chem. Sci., 2015, 6, 6865–6871that would otherwise hold the side chains of Leu 656 and Ile 653
of the inhibitory helix are nearby and should be available to
bind additional hydrophobic groups of a designed inhibitor
(Fig. 2). The close proximity of these lipophilic amino acids to
one another suggested that disulde versions of a-mercaptoa-
crylic acids might be able to mimic the binding mode of cal-
pastatin. Close inspection of the structure of the inhibitory
region C of the CAST domain IV bound to PEF(S) and molecular
docking experiments revealed the possibility that due to the
stereoelectronic constraints of sulfur–sulfur bonds the two
aromatic rings of a disulde linked linked form of 3 might t
into the two adjacent hydrophobic pockets of PEF(S); in
particular the aromatic groups of such a disulde based
compound may interact with the pockets that bind Leu 656 and
Leu 660 of calpastatin. To test this proposal, the oxidised form
of 3, (2Z,20Z)-2,20-disulfanediylbis(3-(6-bromoindol-3-yl)acrylic
acid), (4, Fig. 1), was generated and the single crystal X-ray
structure of 4 bound to PEF(S) solved.
The rate of conversion of 3 to its disulde form was depen-
dent upon both the concentration of the compound and the
nature of the solution. UV-VIS spectroscopy showed that 3 (100
mM in 100 mM KiPO4, pH 7.0) was completely converted to its
oxidised form 4 in 3 hours at room temperature and was easily
reduced to the sulydryl form by addition of tris(2-carboxy-
ethyl)phosphine (TCEP) (see ESI†). For crystallography, 3 (50
mM) was dissolved in DMSO and le at room temperature for
24 hours, aer which time oxidation was complete according to
1H-NMR spectroscopy (see ESI†). Compound 4 was then added
to preformed crystals of PEF(S).
The electron density map revealed that the ligand adopts two
diﬀerent conformations in each subunit of the PEF(S) homo-
dimer, therefore a total of four conformations of the ligand
were observed in the asymmetric unit of the crystal structure.
The unique geometry of the disulde bond is observed in all of
the conformations ensuring that both pockets of the hydro-
phobic groove of PEF(S) are explored. One of the 6-bromoindole
rings of 4 is bound in the hydrophobic binding pocket that also
binds 3. The aromatic ring is capable of moving within the
pocket, adopting two diﬀerent conformations with the ring
ipped by approximately 180 relative to the other as observed
in chain A of PEF(S) (Fig. 2). The second indole ring of 4
interacts with a hydrophobic groove on the surface of PEF(S),
where the a-helix of CAST inhibitory region C binds with
PEF(S).21 Two diﬀerent binding orientations of the ligand are
observed, allowing for diﬀerent protein residues to interact
with the ligand. In chain A, the second 6-bromoindole ring
resides in a hydrophobic pocket where Leu 656 of CAST also
binds (Fig. 2), whereas in chain B it targets the hydrophobic
groove that binds the peptide backbone of CAST inhibitory
region C (Fig. 2).23
With the exception of a hydrogen bond between the
carboxylate of 3 and the side chain amide group of Gln175 in
chain B, van der Waals forces are the main interactions
observed between 3 and the residues of both monomers of the
protein. A greater number of interactions form between 4 and
residues of PEF(S) than with 3 and the protein, including a
number of electrostatic interactions and hydrogen bonds. InThis journal is © The Royal Society of Chemistry 2015
Fig. 2 (A) Surface representation of chain A of PEF(S) bound to 3 in the hydrophobic pocket that binds Leu 660 (PDB 4WQ2). (B) Inhibitory region
C of the CAST domain IV bound to PEF(S); Ile 653, Leu 656 and Leu 660 are highlighted (PDB 3BOW).23 (C) 4 bound to chain A of PEF(S); a single
binding mode of 4 is represented (PDB 4WQ3).




















































































View Article Onlinechain A, six hydrophilic interactions between the two confor-
mations of 4 and Arg130, His131 and Trp168 are observed
(Fig. 3). An electrostatic bond forms between the carboxylate
group of 4 and the positively charged guanidinium group of
Arg130. Hydrogen bonds are observed between the carboxylates
of the ligand and the side-chain NH groups of His131 and
Trp168 (Fig. 3). A diﬀerent electrostatic interaction is seen
between 4 bound to chain B between a carboxylate group of the
ligand and the NH3
+ group of Lys172 with distances of 2.17 A˚
and 2.51 A˚ for the two conformations (Fig. 3). Interactions form
between the bromine atoms of 4 and hydrophilic groups in
chain B; one bromide interacts with Arg130 and the second with
His131 with Br–N distances of 3.31 A˚ and 3.15 A˚, respectively
(Fig. 3). The greater number of interactions observed between
compound 4 and PEF(S) suggests tighter binding to PEF(S). The
structure of 4 bound to PEF(S) prompted a re-evaluation of the
inhibitory potency of the a-mercaptoacrylic acids previously
synthesised.24 Previously, no special measures had been taken
to ensure that the compounds were in oxidised or reduced form
during the assays. The oxidised and reduced compounds were
now assayed against calpain-I to determine their aﬃnity for
PEF(S).
The inhibitory properties of a series of oxidised and reduced
a-mercaptoacrylic acid derivatives towards calpain-I (Fig. 4)
were assessed in a FRET-based assay in the presence and
absence of 10 mM dithiothreitol (DTT).24,25 To ensure complete
oxidation, compounds were le in the assay solution for 3 hours
prior to performing the assay (vide supra and ESI†). In the
absence of inhibitors there was no observable diﬀerence in
enzyme activity when assayed under both oxidising and
reducing conditions.
When DTT was present, IC50 values were in the micromolar
range for both phenyl and indole based a-mercaptoacrylic acidThis journal is © The Royal Society of Chemistry 2015derivatives (Fig. 4). As observed previously,24 the position of the
halogen in the aromatic ring for phenyl based inhibitors was
important for the inhibitory potency. All 2-substituted
compounds have IC50 values of 50 mM whereas compounds
that are substituted in the 3- or 4-position are about one order
of magnitude more potent. Also, the type of halogen is
important for the potency for the inhibitor in that F substituted
compounds are approximately 10-fold weaker inhibitors than
the corresponding Br and I substituted inhibitors. This trend
does not hold for Cl and Br substituents in the 2 position,
which bind with aﬃnities of 60 mM and 50 mM, respectively
(Fig. 4). The indole based a-mercaptoacrylic acid derivatives
showed IC50 values in the low micromolar range in the pres-
ence of DTT and there was no obvious trend with respect to
position or type of halogen (Fig. 4). The IC50 values reported
here are higher than previously reported for the same
compounds, most likely due to the presence of poorly dened
mixtures of reduced and oxidised mercaptoacrylic acids in
previous experiments.14–17,20,24
For the oxidised compounds IC50 values were in the nano-
molar range, a 10- to 200-fold increase in potency, indicating
that the thiol group is not important for inhibition of calpain-I.
The IC50 values for the phenyl derivatives range from 7.5 to 250
nM. The position of the halogen was important for the potency
of the inhibitor with a trend similar to that observed for the
reduced compounds. Iodo substituted compounds (17 and 23)
showed IC50 values of 25 nM and 7.5 nM, respectively (Fig. 4).
With the exception of the iodo-substituent the type of halogen
appears to have little importance for IC50 values. The indole
based disulde compounds show a 10- to 150-fold increase in
potency relative to the free sulydryls. IC50 values ranged from
10 to 28 nM, with the exception of 3, which was less potent (IC50
¼ 100 nM) (Fig. 4). No discernible trend was observed withChem. Sci., 2015, 6, 6865–6871 | 6867
Fig. 3 Comparison of the two conformations 4 (cyan) bound to chain A (yellow) of the PEF(S) homodimer, (A) and (B) respectively, and chain B
(green) of the homodimer, (C) and (D) respectively. Residues that form halogen bonds, hydrogen bonds and electrostatic interactions are
highlighted and important bonds are indicated by dashed lines, distances are shown in A˚ (PDB 4WQ2 and 4WQ3).




















































































View Article Onlinerespect to the position or type of halogen relative to the potency
of the inhibitor (Fig. 4). The most potent inhibitor in this series
was the disulde of PD150606 (23), which when tested against
calpain-I gave an IC50 value of 7.5 nM, much more potent than
the Ki value of 0.21 mM, possibly due to the inhibition of calpain-
I being measured in a poorly dened redox buﬀer (Fig. 4).20 The
increased potency of PD150606 in the disulde form 23 led us to
an examination of the co-crystal structure PEF(S) with this
inhibitor in oxidised form.21,22 The structure obtained shows a
lower electron density around the model of the ligand 23 to that
observed for 4, though upon comparison of the two structures
both ligands adopt similar conformations and form analogous
interactions with the protein (see ESI†).
The disulde bond is the only group in the structure of the
oxidised a-mercaptoacrylic acids that allows for exibility
within the molecule. However in agreement with the design,
this exibility is limited due to the specic stereoelectronic
properties of S–S bonds. Rotation around the disulde bond is
restricted due to the repulsive interactions of the lone pairs of
each sulfur atom.29 Dihedral angles of aromatic disuldes are
typically between 100 and 106,29,30 although the dihedral angles
can be both greater and smaller depending upon the6868 | Chem. Sci., 2015, 6, 6865–6871substituents.31 The dihedral angles of the observed conforma-
tions of 4 bound to PEF(S) are 30, 91, 128 and 169. The
dihedral angle of 91 in chain A is close to the optimum
dihedral angle and in this conformation 4 makes strong inter-
actions with both hydrophobic pockets of PEF(S) (Fig. 5).
Disulde bonds are on average 2.08 A˚, approximately 0.5 A˚
longer than a carbon–carbon single bond. The S–S bond length
of 4 bound to PEF(S) ranges from 2.06 to 2.11 A˚.32 The slightly
increased bond length allows for the second aryl group to
interact with the hydrophobic pocket that binds Leu 656 of
calpastatin. To establish whether the properties of the disulde
bond were indeed responsible for the strong inhibitory of
compounds such as 4, one of the sulfur atoms was replaced with
a methylene group to generate a series of thioethers. The rela-
tively unhindered rotation around carbon–sulphur bonds
should lead to a greater loss of entropy when they bind to PEF(S)
and hence to reduced stability compared to the disulde
complexes.
Symmetric and asymmetric thioether compounds were syn-
thesised in a four-step procedure (Fig. 6). A halogenated benz-
aldehyde was reacted with methyl acrylate, followed by base
catalysed hydrolysis of the ester and treatment with aqueousThis journal is © The Royal Society of Chemistry 2015
Fig. 4 IC50 values (mM) for the a-mercaptoacrylic acid compounds tested in FRET based inhibition assays in the presence (sulfhydryl) and
absence (disulﬁde) of 10 mM DTT.
Fig. 5 Representation of 4 with a dihedral angle of 90.5 bound to
chain A of PEF(S).




















































































View Article Onlinehydrogen bromide to generate an allylic bromide derivative,
which was used to alkylate an a-mercaptoacrylic acid.24 All IC50
values of were in the micro-molar range between 1.8 and 10 mM
except for 41 (IC50 ¼ 100 mM) and DTT had no eﬀect on the
potency (Fig. 6). With an IC50 value of 1.8 mM the asymmetric 42
was the most potent thioether examined. The IC50 valuesThis journal is © The Royal Society of Chemistry 2015measured were higher than those obtained for all the disuldes
examined here and indeed generally higher than the free sulf-
hydryls. Also, there was no discrimination between the
symmetric (40) and asymmetric (41, 42 and 43) thioether
derivatives with regards to the eﬃcacy of these compounds
towards calpain-I.
Inhibition data for the thioether-based compounds supports
the importance of the stereoelectronic properties of the S–S
bond for the potency of the mercaptoacrylic acid based inhibi-
tors. The greater degree of exibility of the thioether bond leads
to higher entropic penalty when these compounds ‘lock’ into
position on PEF(S), which in turn produces higher IC50 values.
In addition, the decreased bond length of the C–S bond relative
to the S–S bond may lead to a suboptimal interaction of the
second aromatic ring with the hydrophobic pocket of PEF(S)
that binds Leu 656 of CAST. Crystallographic results support
this rationalisation of the low PEF(S) binding aﬃnity of the
thioethers. Single crystals of PEF(S) were individually soaked
with 40, 42 and 43 and the resulting crystals analysed. The X-ray
diﬀraction data indicated only partial occupancy of the cal-
pastatin binding site. Models representing compounds 40, 42
and 43 were placed into each of the 2F0  Fc maps revealing a
maximum occupancy of the ligands within the electron density
of 30% (see ESI†).Chem. Sci., 2015, 6, 6865–6871 | 6869
Fig. 6 (A) Synthetic route to the thioether calpain inhibitors. (i)
DABCO, MeOH, 25 C, 72 h, (ii) NaOH, MeOH, 25 C, 16 h, (iii) HBr,
H2SO4, 25 C, 16 h, (iv) NEt3, MeCN, 25 C, 16 h. (B) Symmetric and
asymmetric compounds 40–43. (Z)-3-(4-Bromophenyl)-2-((((Z)-2-
(4-bromophenyl)-1-carboxyvinyl)thio)methyl)acrylic acid (40), (Z)-3-
(3-chlorophenyl)-2-((((Z)-2-(4-chlorophenyl)-1-carboxyvinyl)thio)-
methyl)acrylic acid (41), (Z)-3-(5-bromoindol-3-yl)-2-(((Z)-2-carboxy-
3-(3-chlorophenyl)allyl)thio)acrylic acid (42) and (Z)-3-(6-bro-
moindol-3-yl)-2-(((Z)-3-(4-bromophenyl)-2-carboxyallyl)thio)acrylic
acid (43).





















































































The work described here reveals a novel mechanism for inhi-
bition of calpain-I by a-mercaptoacrylic acid derivatives. Based
on the X-ray crystal structure of PEF(S) bound to (Z)-3-(6-bro-
moindol-2-yl)-2-mercaptoacrylic acid (3), oxidised a-mercap-
toacrylic acids such as 4 were designed to target the full
calpastatin binding cavity. The restricted geometry of the
disulphide bond facilitated a larger number of favourable
binding interactions with PEF(S) so that the two aromatic rings6870 | Chem. Sci., 2015, 6, 6865–6871of 4 interact with the hydrophobic pockets that bind Leu 660
and Leu 656 of calpastatin. All disulde linked compounds
acted as potent inhibitors of calpain-I and were up to 200 times
more potent than their reduced counterparts. The dramatic
increase in potency of the oxidised inhibitors can be tentatively
explained by the stereoelectronic properties of S–S bonds such
as the reduced rotations around the S–S bond and the approx-
imately 90 dihedral angles. Accordingly, thioether analogues
were much less potent than their disulde counterparts.
These results open the way to the development of inhibitors
that combine the conformational restrictions of the S–S bond
with reduced sensitivity to reduction. Diselenides are charac-
terised by dihedral angles of 101–106 and bond lengths of
approximately 2.3 A˚, values similar to those found in disuldes.
However, diselenides are more stable towards reduction than
disuldes.33–35 The incorporation of diselenide bonds could
therefore lead to highly potent drugs and cell biology tools that
are stable to the reducing conditions found in the cellular
environment.
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